Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting

Simple item page
dc.contributor.authorBijal Shah
dc.contributor.authorMei Xue
dc.contributor.authorWesley Furnback
dc.contributor.authorKeri Yang
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:01:06Z
dc.date.available2026-03-22T14:01:06Z
dc.date.issued2025
dc.descriptionCitaciones: 2
dc.description.abstractIn this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.
dc.identifier.doi10.1080/14796694.2025.2554354
dc.identifier.urihttps://doi.org/10.1080/14796694.2025.2554354
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/44061
dc.language.isoen
dc.publisherFuture Medicine
dc.relation.ispartofFuture Oncology
dc.sourceMoffitt Cancer Center
dc.subjectIbrutinib
dc.subjectMedicine
dc.subjectBruton's tyrosine kinase
dc.subjectMantle cell lymphoma
dc.subjectOncology
dc.subjectInternal medicine
dc.subjectTyrosine kinase
dc.subjectCancer research
dc.subjectLymphoma
dc.titleReal-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting
dc.typearticle

Files

Collections

Artículo Científico Publicado